skip to Main Content

Pharma Reputations: Managing Perceptions

  • 14 August 2012

Geneva-based Covalence, a company that markets the information system, EthicalQuote, has observed that pharma is not keeping pace with other industries in terms of the overall balance of global good and bad news coverage in four broad ethical areas: labour…


Pledge of $150m to fight neglected diseases

  • 14 October 2010

Six pharmaceutical companies and several governments have pledged more than $150m in medicines and funding over five years to tackle some of the most neglected diseases. The debilitating illnesses — including leprosy, lymphatic filariasis and sleeping sickness — affect 1bn…


J&J Giving $200M To Fund Countries Health

  • 8 September 2010

Health giant Johnson & Johnson is donating about $200 million in cash and medicine to a sweeping United Nations program created to improve the health and lives of people in poor countries. J&J is launching a five-year program called "Every…


Applications for Business Excellence Awards Being Accepted

  • 11 December 2008

The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria is inviting submissions for the 2009 Awards for Business Excellence, which will honor the unique and crucial contributions of companies implementing sophisticated, successful programs to fight disease. Winners of the Coalition's…


PepsiCo, Kohl’s Among Cos. Honored for Green Power Purchases

  • 23 October 2007

The U.S. Environmental Protection Agency on Monday honored 17 companies that combined buy nearly 4 billion kilowatt hours of green power each year. The Green Power Purchasing Leaders already are Green Power Partners that commit to buying renewable power such…


The Burden of Innovation – Covalence Pharmaceutical Industry Report 2007

  • 29 August 2007

Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical…


After Sanctions, Doctors Get Drug Company Pay

  • 3 June 2007

A decade ago the Minnesota Board of Medical Practice accused Dr. Faruk Abuzzahab of a “reckless, if not willful, disregard” for the welfare of 46 patients, 5 of whom died in his care or shortly afterward. The board suspended his…

Back To Top